#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Heart disease congenital Aspergillus infection Ichthyosis Small intestine neuroendocrine tumour Lymphatic malformation High-grade B-cell lymphoma Primary hyperoxaluria Nasopharyngeal cancer Cytokine release syndrome Hereditary optic atrophy Glomerulonephritis rapidly progressive Systemic sclerosis pulmonary Non-renal cell carcinoma of kidney Activated PI3 kinase delta syndrome Hodgkin's disease refractory More trials…

    Learn about Rare Diseases

    Basal cell naevus syndrome Inclusion body myositis – Trials in Disease Turner’s syndrome Progressive multifocal leukoencephalopathy – Life with Disease Wiskott-Aldrich syndrome – Trials in Disease Paroxysmal nocturnal haemoglobinuria – Treatment Antisynthetase syndrome – Treatment Phenylketonuria Mucopolysaccharidosis I – Treatment Ewing’s sarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Adrenaline Tartrate Ph. Eur. Cabozantinib Obexelimab Tin816 Timbetasin Acetate Azd0901 Anhydrous Cholestyramine Milnacipran Hydrochloride Seralutinib Daunorubicin Nilutamide Triptorelin Tinlarebant Linsitinib Fludeoxyglucose (18F) Goserelin Acetate BMS-986470 Pemigatinib Oxybuprocaine Hydrochloride Tyra-300-B01 More therapies…

    Learn about Your Condition

    Atrophic vulvovaginitis Hypopituitarism Foot deformity Bronchostenosis Anxiety disorder Colon cancer Gallbladder cancer Injection site pain Colorectal cancer stage III Arthralgia Vaginal cancer Intellectual disability Thalassaemia alpha Epileptic encephalopathy Hidradenitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut De Cancerologie De Lorraine

Institut De Cancerologie De Lorraine

6 Avenue De Bourgogne, Cs 30519, Vandoeuvre Les Nancy, 54519, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Improving Treatment for Young Adults with Poor-Prognosis Non-Seminomatous Germ-Cell Tumors Using Paclitaxel and Drug Combination

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Lenograstim
    • Bleomycin Sulfate
    • Mesna
    France

  • Study on ONC201 and Everolimus with Radiotherapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Other Diffuse Midline Gliomas in Children, Adolescents, and Adults

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Brain stem glioma
    Investigated Drugs:
    • 2,4,6,7,8,9-Hexahydro-4-((2-Methylphenyl)Methyl)-7-(Phenylmethyl)Imidazo(1,2-A)Pyrido(3,4-E)Pyrimidin-5(1H)-One
    • Everolimus
    Belgium Denmark Finland France Greece Norway +2

  • Study of Pemigatinib for Patients with Recurrent or Metastatic Solid Tumors with FGFR Gene Alteration

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Pemigatinib
    France

  • Study on Oxaliplatin with Drug Combination for Patients with Advanced Peritoneal Metastasis from Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Bevacizumab
    • Capecitabine
    • Cetuximab
    France

  • Study on Dostarlimab and Niraparib for Patients with Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Endometrial cancer recurrent
    • Ovarian cancer
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    France Italy Spain

  • Study on Durvalumab and Tremelimumab for Patients with Kidney Cancer at Risk of Recurrence After Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Durvalumab
    • Tremelimumab
    France Spain

  • Study on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Pertuzumab
    • Trastuzumab
    • Trastuzumab Deruxtecan
    France

  • Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Cisplatin
    • Etoposide
    • Fluorouracil
    France

  • Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    Austria Belgium Czechia Finland France Germany +10

  • Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Camizestrant
    • Ribociclib
    France Germany Italy Poland Spain
Previous Page
1 … 7 8 9 10 11 … 18
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!